Overview
KRRO market data
Price History
KRRO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$12.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,834.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.20 – $55.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $201.4M · P/B 1.47 · P/S 31.52.
Company News
Korro Bio Q2 EPS $(1.07) Beats $(1.31) EstimateBenzinga · Aug 6, 2026, 11:28 AM
8-K filing — Korro Bio, Inc. (KRRO)SEC EDGAR · Aug 6, 2026, 11:04 AM
Korro Bio shares are trading lower after a Form 4 filing showed its President and CEO sold 15,152 shares at an average price of $12.98 each.Benzinga · Jun 2, 2026, 6:50 PM
Korro Bio Announces Addition Of KRRO-111 For Potential Treatment Of AATD To Pipeline Of Therapeutic Programs In DevelopmentBenzinga · May 19, 2026, 11:20 AM
Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21Benzinga · May 18, 2026, 1:40 PM